Malignant Pleural Mesothelioma Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight

Malignant Pleural Mesothelioma Companies are AstraZeneca, PharmaMar, Ferring Ventures Limited, Polaris Pharmaceuticals, TCR2 Therapeutics, ETOP IBCSG Partners Foundation, Nurix Therapeutics, Context Therapeutics, Amphera BV, Sellas Life Sciences Group, Momotaro-Gene, Targovax, Hoffmann-La Roche, and others
(Albany, USA) DelveInsight's "Malignant Pleural Mesothelioma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Malignant Pleural Mesothelioma, historical and forecasted epidemiology as well as the Malignant Pleural Mesothelioma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Malignant Pleural Mesothelioma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Malignant Pleural Mesothelioma Market Forecast [https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Malignant Pleural Mesothelioma Market Report:

* The Malignant Pleural Mesothelioma market size was valued approximately USD 310 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In February 2025, Ferring Ventures Limited announced results of a Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma
* In January 2025, Nurix Therapeutics, Inc. announced results of a Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
* In January 2025, Context Therapeutics Inc announced results of Phase 1 Study of CT-95 in Advanced Cancers Associated with Mesothelin Expressionz
* In January 2025, ETOP IBCSG Partners Foundation announced results of a Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
* In September 2024, The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for unresectable advanced or metastatic malignant pleural mesothelioma (MPM). This approval was supported by data from the phase 2/3 KEYNOTE-483 clinical trial, which enrolled 440 patients with unresectable advanced or metastatic MPM who had not previously received systemic therapy for advanced disease.
* In the seven major markets (7MM), the United States recorded the highest number of pleural effusion incident cases in 2023, representing approximately 40% of the total cases.
* In the United States, approximately 75% of the total incident cases of malignant pleural effusion were diagnosed, while the remaining cases went undiagnosed.
* In the EU4 and the UK, Germany represents the largest share of diagnosed malignant pleural effusion cases, making up approximately 25% of the total diagnosed cases in the region.
* In the 7MM, based on tumor type, malignant pleural effusion was most frequently associated with lung cancer, comprising approximately 30% of diagnosed cases, followed by breast cancer.
* Key Malignant Pleural Mesothelioma Companies: AstraZeneca, PharmaMar, Polaris Pharmaceuticals, TCR2 Therapeutics, Amphera BV, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, Targovax, Hoffmann-La Roche, and others
* Key Malignant Pleural Mesothelioma Therapies: IMFINZI, Lurbinectedin, Pegargiminase, TC-210, MesoPher, Galinpepimut-S (Vaccine), MTG201 + nivolumab, ZEPZELCA (lurbinectedin), ONCOS-102, TECENTRIQ Plus AVASTIN, and others
* The Malignant Pleural Mesothelioma epidemiology based on gender analyzed that males are more at risk of developing MPM in comparison to the females
* In the year 2022, there were a total of 1,400 cases of Malignant Pleural Mesothelioma in males and 400 cases in females in the United States
* The Malignant Pleural Mesothelioma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Malignant Pleural Mesothelioma pipeline products will significantly revolutionize the Malignant Pleural Mesothelioma market dynamics.

Malignant Pleural Mesothelioma Overview

Malignant Pleural Mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleura, the thin lining surrounding the lungs. It is primarily caused by asbestos exposure, with a long latency period of 20-50 years before symptoms appear. Common Malignant Pleural Mesothelioma symptoms include chest pain, shortness of breath, persistent cough, pleural effusion, and unexplained weight loss. Due to its aggressive nature and late-stage diagnosis, Malignant Pleural Mesothelioma has a poor prognosis, with a median survival of 12-18 months.

Malignant Pleural Mesothelioma Diagnosis involves imaging techniques such as CT scans, PET scans, and MRI, followed by biopsy and histopathological analysis. Key Malignant Pleural Mesothelioma biomarkers like calretinin, WT-1, and mesothelin help differentiate Malignant Pleural Mesothelioma from other pleural diseases. Malignant Pleural Mesothelioma Treatment options include surgery (pleurectomy/decortication or extrapleural pneumonectomy), chemotherapy (cisplatin and pemetrexed), radiation therapy, and emerging immunotherapy and targeted therapies. FDA-approved immune checkpoint inhibitors (nivolumab and ipilimumab) have improved survival rates in some patients.

Despite ongoing Malignant Pleural Mesothelioma clinical trials and research in novel treatments, Malignant Pleural Mesothelioma remains a challenging cancer with limited curative options. Early detection, advancements in personalized medicine, multimodal therapy, and biomarker-driven approaches are crucial in improving patient outcomes. Increasing awareness and asbestos exposure regulations are key to reducing future incidence rates.

Get a Free sample for the Malignant Pleural Mesothelioma Market Report: Malignant Pleural Mesothelioma Treatment Market [https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Malignant Pleural Mesothelioma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Malignant Pleural Mesothelioma Epidemiology Segmentation:

The Malignant Pleural Mesothelioma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of Malignant Pleural Mesothelioma
* Prevalent Cases of Malignant Pleural Mesothelioma by severity
* Gender-specific Prevalence of Malignant Pleural Mesothelioma
* Diagnosed Cases of Episodic and Chronic Malignant Pleural Mesothelioma

Download the report to understand which factors are driving Malignant Pleural Mesothelioma epidemiology trends @ Malignant Pleural Mesothelioma Epidemiology Forecast [https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Malignant Pleural Mesothelioma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Malignant Pleural Mesothelioma market or expected to get launched during the study period. The analysis covers Malignant Pleural Mesothelioma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Malignant Pleural Mesothelioma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Malignant Pleural Mesothelioma Therapies and Key Companies

* IMFINZI: AstraZeneca
* Lurbinectedin: PharmaMar
* Pegargiminase: Polaris Pharmaceuticals
* TC-210: TCR2 Therapeutics
* MesoPher: Amphera BV
* Galinpepimut-S (Vaccine): Sellas Life Sciences Group
* MTG201 + nivolumab: Momotaro-Gene
* ZEPZELCA (lurbinectedin): PharmaMar
* ONCOS-102: Targovax
* TECENTRIQ Plus AVASTIN: Hoffmann-La Roche

Request for sample page to know more about the drugs and therapies @ Malignant Pleural Mesothelioma Companies and Treatment [https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Malignant Pleural Mesothelioma Market Strengths

* Various drugs in the pipeline like ADI-PEG 20, ONCOS-102, MesoPher, and others have an ODD which will grants seven years of market exclusivity in the US along with clinical trials subsidies and reduced regulatory fees
* The ODD granted to these emerging drugs will also enable the companies to launch them at premium prices

Malignant Pleural Mesothelioma Market Opportunities

* Recent developments in blood-based biomarkers seen in recent years and can serve several potential roles in MPM like diagnostics, prognostics, or predictive of response to specific therapies
* There is a potential for companies to price their drugs at a premium price if their therapies provide an edge over the current therapies like nivolumab

Scope of the Malignant Pleural Mesothelioma Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Malignant Pleural Mesothelioma Companies: AstraZeneca, PharmaMar, Polaris Pharmaceuticals, TCR2 Therapeutics, Amphera BV, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, Targovax, Hoffmann-La Roche, and others
* Key Malignant Pleural Mesothelioma Therapies: IMFINZI, Lurbinectedin, Pegargiminase, TC-210, MesoPher, Galinpepimut-S (Vaccine), MTG201 + nivolumab, ZEPZELCA (lurbinectedin), ONCOS-102, TECENTRIQ Plus AVASTIN, and others
* Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
* Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Malignant Pleural Mesothelioma Unmet Needs, KOL's views, Analyst's views, Malignant Pleural Mesothelioma Market Access and Reimbursement

To know more about Malignant Pleural Mesothelioma companies working in the treatment market, visit @ Malignant Pleural Mesothelioma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Malignant Pleural Mesothelioma Market Report Introduction

2. Executive Summary for Malignant Pleural Mesothelioma

3. SWOT analysis of Malignant Pleural Mesothelioma

4. Malignant Pleural Mesothelioma Patient Share (%) Overview at a Glance

5. Malignant Pleural Mesothelioma Market Overview at a Glance

6. Malignant Pleural Mesothelioma Disease Background and Overview

7. Malignant Pleural Mesothelioma Epidemiology and Patient Population

8. Country-Specific Patient Population of Malignant Pleural Mesothelioma

9. Malignant Pleural Mesothelioma Current Treatment and Medical Practices

10. Malignant Pleural Mesothelioma Unmet Needs

11. Malignant Pleural Mesothelioma Emerging Therapies

12. Malignant Pleural Mesothelioma Market Outlook

13. Country-Wise Malignant Pleural Mesothelioma Market Analysis (2020-2034)

14. Malignant Pleural Mesothelioma Market Access and Reimbursement of Therapies

15. Malignant Pleural Mesothelioma Market Drivers

16. Malignant Pleural Mesothelioma Market Barriers

17. Malignant Pleural Mesothelioma Appendix

18. Malignant Pleural Mesothelioma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=malignant-pleural-mesothelioma-treatment-market-2034-ema-pdma-fda-approvals-clinical-trials-nda-approvals-medication-prevalence-moa-revenue-statistics-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.